Build Patient-Site Trust to Improve Clinical Trial Retention

Andrea Valente serves as the Chief Executive Officer (CEO) for uMotif. She brings over 20 years of achievement across the life sciences technology industry including positions of global leadership in product development, delivery operations, customer loyalty and M&A activity.

Prior to her appointment as CEO, Valente served as uMotif’s Chief Operating Officer (COO). Her operational leadership, deep industry knowledge and patient- and site-centric focus have reinforced uMotif’s reputation as a trusted provider of modern eCOA and eConsent solutions and services.

Before joining uMotif, Valente was CEO of eConsent provider ClinOne, which uMotif acquired in September 2024. Valente’s prior roles also include COO at Medable and VP of Pandemic Response Systems at Oracle, where she led business development, product development and service delivery of the cloud-based Oracle Health Management System (OHMS). Valente also served as EVP, Chief Development Officer at ERT, where she was responsible for global R&D and IT. She played a key role in four strategic acquisitions and the sale of ERT to Nordic Capital.

Ken Getz is the Executive Director of the Tufts Center for the Study of Drug Development and a Research Professor at the Tufts University School of Medicine. He is an internationally recognized expert on pharmaceutical R&D management and execution, protocol design, contract service provider and investigative site management, eClinical technology and data usage and patient engagement. A well-known speaker at conferences, symposia, universities, investor meetings and corporations, Ken has published extensively in peer-reviewed journals, books and in the trade press. He holds several board appointments in the private and public sectors.

He received his MBA from the J.L. Kellogg Graduate School of Management at Northwestern University and his Bachelor’s degree from Brandeis University. Ken is also the Chairman of CISCRP, a nonprofit organization that he founded to educate and raise public and patient awareness of the clinical research enterprise, and the Founder of CenterWatch, a leading publisher in the clinical trials industry and one of several businesses that he has sold.

Dr. Ian Hodgson serves as Chief Operating Officer at Corbus Pharmaceuticals. Dr. Hodgson has over 25 years of experience in drug development and operations across biotech, large pharmaceutical companies and contract research organizations.

Dr. Hodgson joined Corbus International Ltd. as Head of Clinical and European Operations and transitioned to Head of Operations prior to his current role. Since May 2021, Dr. Hodgson has served as a Non-Executive Director and Board Advisor for MD Group Ltd., a privately owned patient services company and Skyelarke, a health-tech company specializing in delivering patient payments in clinical trials. Previously, he held several leadership positions, including Vice President, Head of Clinical Services at TMC Pharma Services Ltd., a rare disease consultancy; Vice President, Clinical Development – Rare Diseases at Syneos Health and Head of Clinical Operations at Mereo Biopharma. 

Dr. Hodgson earned a PhD in Medical Microbiology from Queen Margaret University in collaboration with the University of Edinburgh (awarded by the Open University) and a BSc (Hons) in Food Technology from Reading University.

Aneesh Vaze is the Managing Director of Clinical Research Philadelphia (CRP), a premier site with 500+ completed trials since 1996. CRP drives patient diversity and access by partnering with community providers, utilizing AI-based EMR mining across 650,000+ patients to accelerate enrollment.

Before CRP, Aneesh was a Principal at Herspiegel Consulting, advising pharma and biotech firms on regulatory strategy and commercial launches. Blending sponsor-side insight with operational expertise, he is dedicated to building scalable, efficient research models that bring life-saving therapies to market faster.